# Biomarkers bij HF met centrale slaapapneu: SERVE-HF

*geplaatst 2020-04-01 · Hartfalen · ESC heart failure · doi 10.1002/ehf2.12521 · https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/*

SERVE-HF subanalyse naar biomarkers bij hartfalenpatiënten met centrale slaapapneu.

## English: Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE-HF trial.

This SERVE-HF biomarker analysis characterized biomarker profiles in heart failure patients with central sleep apnea, exploring whether circulating markers identify patients at risk from adaptive servo-ventilation therapy.

## Abstract (original, from the publication)

AIMS: The Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients with Heart Failure trial investigated the effects of adaptive servo-ventilation (ASV) (vs. control) on outcomes of 1325 patients with heart failure and reduced ejection fraction (HFrEF) and central sleep apnoea (CSA). The primary outcome (a composite of all-cause death or unplanned HF hospitalization) did not differ between the two groups. However, all-cause and cardiovascular (CV) mortality were higher in the ASV group. Circulating biomarkers may help in better ascertain patients' risk, and this is the first study applying a large set of circulating biomarkers in patients with both HFrEF and CSA. METHODS AND RESULTS: Circulating protein-biomarkers (n = 276) ontologically involved in CV pathways, were studied in 749 (57% of the trial population) patients (biomarker substudy), to investigate their association with the study outcomes (primary outcome, CV death and all-cause death). The mean age was 69 ± 10 years, and > 90% were male. The groups (ASV vs. control and biomarker substudy vs. no biomarker) were well balanced. The "best" clinical prognostic model included male sex, systolic blood pressure < 120 mmHg, diabetes, loop diuretic, cardiac device, 6-min walking test distance, and N-terminal pro BNP as the strongest prognosticators. On top of the "best" clinical prognostic model, the biomarkers that significantly improved both the discrimination (c-index) and the net reclassification index (NRI) of the model were soluble suppression of tumorigenicity 2 for the primary outcome; neurogenic locus notch homolog protein 3 (Notch-3) for CV-death and all-cause death; and growth differentiation factor 15 (GDF-15) for all-cause death only. CONCLUSIONS: We studied 276 circulating biomarkers in patients with HFrEF and central sleep apnoea; of these biomarkers, three added significant prognostic information on top of the best clinical model: soluble suppression of tumorigenicity 2 (primary outcome), Notch-3 (CV and all-cause death), and GDF-15 (all-cause death).

Auteurs: João Pedro Ferreira, Kévin Duarte, Holger Woehrle, Martin R Cowie, Karl Wegscheider, Christiane Angermann, Marie-Pia d'Ortho, Erland Erdmann, Patrick Levy, Anita K Simonds, Virend K Somers, Helmut Teschler, Patrick Rossignol, Wolfgang Koenig, Faiez Zannad

---
Bron: ESC heart failure, https://doi.org/10.1002/ehf2.12521. Bijgewerkt 2026-07-03T13:27:39Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.